关注
Vinay Prasad, MD MPH
标题
引用次数
年份
¿ Por qué nunca se ha demostrado que el cribado del cáncer salve vidas?
V Prasad, J Lenzer, DHN Fuente
1349 EDITOR’S NOTE
JC Ballantyne, MD Sullivan, A Kolodny, RR Khanna, RG Victor, ...
ARCH INTERN MED 172 (17), 2012
2012
A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature
G Nishikawa, J Luo, V Prasad
European Journal of Cancer 101, 143-151, 2018
202018
A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals
D Herrera-Perez, A Haslam, T Crain, J Gill, C Livingston, V Kaestner, ...
Elife 8, e45183, 2019
1152019
A conversation with Vinay Prasad, MD: To'first, do no harm,'you must start with good evidence
V Prasad
2016
A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices
V Prasad, A Vandross, C Toomey, M Cheung, J Rho, S Quinn, SJ Chacko, ...
Mayo Clinic Proceedings, 2013
4382013
A further strategy to combat the high price of anticancer drugs
V Prasad, K De Jesús, S Mailankody
Nature Reviews Clinical Oncology 14 (10), 629, 2017
42017
À la carte medicine
V Prasad
Canadian Medical Association Journal 182 (18), 2011-2012, 2010
2010
A medical burden of proof: Towards a new ethic
V Prasad, A Cifu
Biosocieties, doi: 10.1057/biosoc.2011., 2012
232012
A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment
J Gill, V Prasad
Research and Practice in Thrombosis and Haemostasis 4 (1), 19, 2020
12020
A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer
K Powell, T Olivier, V Prasad
Trials 23 (1), 1044, 2022
12022
A pooled analysis of published, basket trials in cancer medicine
A Hazim, V Prasad
European Journal of Cancer 101, 244-250, 2018
212018
A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers
V Prasad, A Haslam, J Tuia
Journal of Cancer Policy 31, 100319, 2022
12022
A reality check of the accelerated approval of immune-checkpoint inhibitors
J Gill, V Prasad
Nature Reviews Clinical Oncology 16 (11), 656-658, 2019
352019
A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials
A Maniar, V Prasad, A Haslam
2021
A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target
A Haslam, T Olivier, J Tuia, V Prasad
European Journal of Cancer 178, 227-233, 2023
32023
A Systematic Review of Evidence Behind the CDC Guidelines for Indoor Lightning Safety
V Prasad, EMD Brown, A Haslam
medRxiv, 2023.10. 05.23296621, 2023
2023
A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda
J Luo, G Nishikawa, V Prasad
Journal of Cancer Research and Clinical Oncology 145, 2303-2311, 2019
112019
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
A Haslam, SP Hey, J Gill, V Prasad
European Journal of Cancer 106, 196-211, 2019
1712019
A timeline of immune checkpoint inhibitor approvals in small cell lung cancer
J Gill, JP Cetnar, V Prasad
Trends in Cancer 6 (9), 736-738, 2020
62020
系统目前无法执行此操作,请稍后再试。
文章 1–20